TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Part of paid clinical trials in San Antonio, Texas.
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Study ID
- NCT03032484
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUGBevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
- TVB-2640 — DRUGTVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
Study Details
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
Key Dates
- First listed
- Jan 26, 2017
- Start date
- May 18, 2017
- Status verified
- Jun 2023
- Primary completion
- Apr 4, 2020
- Completion
- Apr 5, 2021
Study Design
- Enrollment
- 25 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Bevacizumab and TVB-2640Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
- Experimental: Bevacizumab for Cycle 1, then Bevacizumab and TVB-2640Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle, and then receive both Bevacizumab and TVB-2640 for the remainder of their participation in this study.
Primary Outcome Measure
Progression Free Survival at 6 Months (PFS6) [ Time Frame: 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center | San Antonio | Texas | 78229 | - |
Find similar trials in San Antonio, TX
By condition
By specialty
Related Studies
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsPHASE1 · Recruiting · M.D. Anderson Cancer Center · Birmingham, Alabama
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaPHASE1 · Recruiting · Orbus Therapeutics, Inc. · Birmingham, Alabama
- Study of Olutasidenib and Temozolomide in HGGPHASE2 · Recruiting · Rigel Pharmaceuticals · Aurora, Colorado
- Implantable Microdevice In Primary Brain TumorsEARLY_PHASE1 · Recruiting · Oliver Jonas · Boston, Massachusetts